Orgenesis Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.68
- Today's High:
- $0.7345
- Open Price:
- $0.7029
- 52W Low:
- $0.38
- 52W High:
- $2.64
- Prev. Close:
- $0.7
- Volume:
- 26430
Company Statistics
- Market Cap.:
- $21.42 million
- Book Value:
- 0.842
- Revenue TTM:
- $35.63 million
- Operating Margin TTM:
- -17.14%
- Gross Profit TTM:
- $36.03 million
- Profit Margin:
- -38.64%
- Return on Assets TTM:
- -6.49%
- Return on Equity TTM:
- -38%
Company Profile
Orgenesis Inc had its IPO on 2012-03-12 under the ticker symbol ORGS.
The company operates in the Healthcare sector and Biotechnology industry. Orgenesis Inc has a staff strength of 167 employees.
Stock update
Shares of Orgenesis Inc opened at $0.7 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.68 - $0.73, and closed at $0.69.
This is a -2.13% slip from the previous day's closing price.
A total volume of 26,430 shares were traded at the close of the day’s session.
In the last one week, shares of Orgenesis Inc have increased by +18.12%.
Orgenesis Inc's Key Ratios
Orgenesis Inc has a market cap of $21.42 million, indicating a price to book ratio of 1.6996 and a price to sales ratio of 1.779.
In the last 12-months Orgenesis Inc’s revenue was $35.63 million with a gross profit of $36.03 million and an EBITDA of $-3929000. The EBITDA ratio measures Orgenesis Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Orgenesis Inc’s operating margin was -17.14% while its return on assets stood at -6.49% with a return of equity of -38%.
In Q1.6666666666667, Orgenesis Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.1%.
Orgenesis Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Orgenesis Inc’s profitability.
Orgenesis Inc stock is trading at a EV to sales ratio of 2.6297 and a EV to EBITDA ratio of -6.0303. Its price to sales ratio in the trailing 12-months stood at 1.779.
Orgenesis Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $54.77 million
- Total Liabilities
- $12.71 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $511000
- Dividend Payout Ratio
- 0%
Orgenesis Inc ended 2024 with $54.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $54.77 million while shareholder equity stood at $23.97 million.
Orgenesis Inc ended 2024 with $0 in deferred long-term liabilities, $12.71 million in other current liabilities, 3000.00 in common stock, $-129577000.00 in retained earnings and $3.70 million in goodwill. Its cash balance stood at $180000.00 and cash and short-term investments were $180000.00. The company’s total short-term debt was $2,616,000 while long-term debt stood at $17.83 million.
Orgenesis Inc’s total current assets stands at $9.30 million while long-term investments were $31.48 million and short-term investments were $0. Its net receivables were $8.03 million compared to accounts payable of $3.83 million and inventory worth $34000.00.
In 2024, Orgenesis Inc's operating cash flow was $0 while its capital expenditure stood at $511000.
Comparatively, Orgenesis Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.69
- 52-Week High
- $2.64
- 52-Week Low
- $0.38
- Analyst Target Price
- $6
Orgenesis Inc stock is currently trading at $0.69 per share. It touched a 52-week high of $2.64 and a 52-week low of $2.64. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $0.96 and 200-day moving average was $1.45 The short ratio stood at 3.85 indicating a short percent outstanding of 0%.
Around 1180.3% of the company’s stock are held by insiders while 1256.9% are held by institutions.
Frequently Asked Questions About Orgenesis Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.